Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis Sho ShiinoCecily QuinnEmad A. Rakha Review Open access 24 November 2022 Pages: 245 - 254
Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis Zhengyan YangHongyun XuMarvin Xuejun Xu Preclinical study 12 November 2022 Pages: 255 - 267
Correlation analysis between shear-wave elastography and pathological profiles in breast cancer Junnan LiBo SunHong Lu Preclinical study 14 November 2022 Pages: 269 - 276
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers Joshua OgonyTanya L. HoskinAmy C. Degnim Preclinical study 16 November 2022 Pages: 277 - 285
Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy Shu YazakiTatsunori ShimoiKan Yonemori Preclinical study Open access 16 November 2022 Pages: 287 - 297
A detailed description of the distress trajectory from pre- to post-treatment in breast cancer patients receiving neoadjuvant chemotherapy Tamara E. LacourtZsuzsa KonczDebu Tripathy Clinical trial 16 November 2022 Pages: 299 - 305
Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer Riley BergmanYvonne A. BerkoBrent N. Rexer Clinical trial 17 November 2022 Pages: 307 - 317
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer Aditya BardiaIngrid MayerKomal Jhaveri Clinical trial Open access 19 November 2022 Pages: 319 - 331
The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery R. L. NussbaumerN. MaggiElisabeth A. Kappos Clinical trial Open access 20 November 2022 Pages: 333 - 341
Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer Huiling WangXiaonan ShengJinsong Lu Clinical trial 21 November 2022 Pages: 343 - 354
Return of individual genomic research results within the PRAEGNANT multicenter registry study Hanna HuebnerMatthias RuebnerLaura L. Michel Clinical trial Open access 21 November 2022 Pages: 355 - 368
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer Sarah E. BurnetteEmily PoehleinHeather N. Moore Clinical trial 21 November 2022 Pages: 369 - 376
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry Samia Kada MohammedTienhan Sandrine Dabakuyo YonliSylvain Ladoire Clinical trial Open access 23 November 2022 Pages: 377 - 385
A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia Andrey KechinUlyana BoyarskikhMaxim Filipenko Epidemiology 11 November 2022 Pages: 387 - 395
Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients Elizabeth JoyceGrant CarrN. Lynn Henry Epidemiology 13 November 2022 Pages: 397 - 404
Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis David GlynnJudith BlissSusan Griffin Epidemiology Open access 17 November 2022 Pages: 405 - 416
Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy? Anita MamtaniAnne GrabenstetterMary L. Gemignani Epidemiology 17 November 2022 Pages: 417 - 423
Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer Laura NotewareGloria BroadwaterSarah Sammons Epidemiology 20 November 2022 Pages: 425 - 434
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database Masaaki KawaiMasahiro TakadaYoshinori Tanizawa Epidemiology Open access 21 November 2022 Pages: 435 - 447
Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study Francisco AcevedoBenjamín WalbaumCésar Sánchez Epidemiology 21 November 2022 Pages: 449 - 459